comparemela.com
Home
Live Updates
Unprecedented 3-Year Sustained Survival in SCLC With New Combo : comparemela.com
'Unprecedented' 3-Year Sustained Survival in SCLC With New Combo
The combination of durvalumab plus etoposide and cisplatin/carboplatin should now become the standard of care for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Related Keywords
Madrid ,
Spain ,
Geneva ,
Genè ,
Switzerland ,
Universidad Complutense Ciberonc ,
Alfredo Addeo ,
Luis Paz ,
University Hospital ,
Astrazeneca ,
Luis Paz Ares ,
Medical Oncology Congress ,
Luniversidad Complutense ,
Lung Cancer ,
Ung Carcinoma ,
Ancer Lung ,
Small Cell Lung Cancer ,
Chemotherapy ,
Anti Ctla4 Antibodies ,
Nti Ctla 4 Antibodies ,
Nti Cytotoxict Lymphocyte Associated Antigen 4 Antibodies ,
Melanoma ,
Malignant Melanoma ,
comparemela.com © 2020. All Rights Reserved.